As of 2025-07-04, the Intrinsic Value of Gene Biotherapeutics Inc (CRXM) is -0.20 USD. This CRXM valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.00 USD, the upside of Gene Biotherapeutics Inc is -19,940,425.00%.
Based on its market price of 0.00 USD and our intrinsic valuation, Gene Biotherapeutics Inc (CRXM) is overvalued by 19,940,425.00%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.20 - -0.20 | -0.20 | -19,940,425.00% |
| P/E | (0.10) - (0.07) | (0.09) | -8953303.8% |
| DDM - Stable | (0.00) - (0.00) | (0.00) | -49991.6% |
| DDM - Multi | (0.00) - (0.00) | (0.00) | -6462.6% |
| Market Cap (mil) | 0.00 |
| Beta | 26.31 |
| Outstanding shares (mil) | 64.93 |
| Enterprise Value (mil) | 0.20 |
| Market risk premium | 4.60% |
| Cost of Equity | 2,305.51% |
| Cost of Debt | 5.00% |
| WACC | 3.92% |